Table 4.
Kappa statistics and 95% confidence interval for the concordance between the JIS, IDF, and ATPIII 2005 metabolic syndrome criteria presented by gender and HIV-related subgroups (N = 748).
| Group and subgroup | Criteria | IDF | JIS |
|---|---|---|---|
| Overall (n = 748) | IDF | — | 0.96 (0.93–0.98) |
| ATPIII 2005 | 0.84 (0.80–0.89) | 0.89 (0.86–0.93) | |
| Men | IDF | — | 0.79 (0.65–0.93) |
| ATPIII 2005 | 0.62 (0.43–0.81) | 0.88 (0.77–0.98) | |
| Women | IDF | — | 0.98 (0.96–1.00) |
| ATPIII 2005 | 0.87 (0.83–0.92) | 0.89 (0.85–0.93) | |
| HIV duration—overall (n = 740) | IDF | — | 0.96 (0.93–0.98) |
| ATPIII 2005 | 0.84 (0.80–0.89) | 0.89 (0.85–0.93) | |
| HIV duration < 5 yrs | IDF | — | 0.96 (0.92–0.99) |
| ATPIII 2005 | 0.81 (0.73–0.89) | 0.86 (0.79–0.92) | |
| HIV duration ≥ 5 yrs | IDF | — | 0.95 (0.92–0.99) |
| ATPIII 2005 | 0.86 (0.80–0.92) | 0.91 (0.87–0.95) | |
| CD4 count—overall (n = 373) | IDF | — | 0.99 (0.97–1.00) |
| ATPIII 2005 | 0.89 (0.84–0.94) | 0.91 (0.86–0.95) | |
| CD4 count < 392 cells/mm3 | IDF | — | 0.99 (0.96–1.00) |
| ATPIII 2005 | 0.86 (0.78–0.95) | 0.88 (0.80–0.96) | |
| CD4 count ≥ 392 cells/mm3 | IDF | — | 0.99 (0.96–1.00) |
| ATPIII 2005 | 0.91 (0.85–0.98) | 0.93 (0.87–0.98) | |
| Antiretroviral therapy use—overall (n = 699) | IDF | — | 0.95 (0.93–0.98) |
| ATPIII 2005 | 0.85 (0.81–0.90) | 0.90 (0.87–0.94) | |
| No antiretroviral treatment | IDF | — | 0.95 (0.86–1.00) |
| ATPIII 2005 | 0.9 (0.77–1.00) | 0.95 (0.86–1.00) | |
| On antiretroviral treatment | IDF | — | 0.95 (0.93–0.98) |
| ATPIII 2005 | 0.85 (0.80–0.90) | 0.90 (0.86–0.94) | |
| 1st-line antiretroviral therapy regimen | IDF | — | 0.96 (0.93–0.99) |
| ATPIII 2005 | 0.86 (0.80–0.92) | 0.91 (0.86–0.95) | |
| 2nd-line antiretroviral therapy regimen | IDF | — | 0.91 (0.81–1.00) |
| ATPIII 2005 | 0.85 (0.72–0.98) | 0.94 (0.86–1.00) | |
| Other antiretroviral therapy regimens | IDF | — | 0.95 (0.90–1.00) |
| ATPIII 2005 | 0.81 (0.71–0.91) | 0.86 (0.77–0.95) |
ATPIII: Adult Treatment Panel III; IDF: International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus. Data were missing for some characteristics. For each grouping variable for which data were missing for some participants, the overall agreement between criteria in that subsample is provided.